Across TCGA pan-cancer cohorts, SPAG11B Mutation is linked to patient survival in 2 of 34 cancer types, making it a survival-associated SPAG11B data layer compared with 15 for mass-spec protein.
The strongest signal is observed in cervical squamous cell carcinoma and endocervical adenocarcinoma (CESC), where higher SPAG11B Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated SPAG11B expression acts as an unfavorable survival marker.
CESC and UCEC are the cancer types where SPAG11B Mutation most reproducibly stratifies survival.